Osteonecrosis of the jaw is a rare complication that has been associated with the use of bisphosphonates. Iv forms of bisphosphonates are used with some cancer treatments and it raises the risks of developing medication related osteonecrosis of the jaw mronj. Oral bisphosphonates alendronate, risedronate and ibandronate, mainly used for the treatment of osteoporosis, have been associated with adverse events from the upper gastrointestinal tract, acute phase response, hypocalcaemia and secondary hyperparathyroidism, musculoskeletal pain. Osteonecrosis of the jaw and atypical subtrochanteric and diaphyseal femur fractures might be related to the use of bisphosphonates in osteoporosis, but they are. Care guidelines are based on expert opinion but clinical decisions are left up to practitioners. Osteonecrosis of the jaws is uncommon in patients who have taken oral bisphosphonates for less than three years. Bisphosphonates and osteonecrosis of the jaw side effect. Jan 01, 2006 the mechanism of bisphosphonates induced osteonecrosis is unclear. Bisphosphonaterelated osteonecrosis of the jaws bronj core. A current update on osteonecrosis of the jaw and bisphosphonates. Pdf bisphosphonateinduced osteonecrosis of the jaw.
With a better understanding of this side effect, reported incidences for bronj in oral bisphosphonate users have. Condition bisphosphonates, like alendronate fosamax, description care management tips osteonecrosis of the jaw onj is a condition where the jawbone is exposed and not covered by gums. Bisphosphonates and osteonecrosis of the jaw bisphosphonate medications are linked to a risk of osteonecrosis of the jaw. We present a case of a 77yearold woman with metastatic breast cancer and osteonecrosis of the jaw after a longterm intravenous treatment with bisphosphonate. Citing the beagle dog study by mashiba and colleagues 2, woo and colleagues state that prolonged use of bisphosphonates may suppress bone turnover to the point that microdamage persists and accumulates, resulting in decreased biomechanical competence. Periodontal disease, dentoalveolar surgery, prior trauma, corticosteroid therapy, immunecompromised state predisposing to increased risk of infection, possible vascular insufficiency and an underlying hypercoagulable state secondary to underlying malignancy have been.
Osteonecrosis of the jaw onj is a very rare side effect of bisphosphonates. If the inline pdf is not rendering correctly, you can download the pdf file here. In this report, we compare the incidence of jaw osteonecrosis among patients with cancer versus patients without cancer who received iv bisphosphonates. Bisphosphonates and osteonecrosis of the jaw bonefos clodronate and didronel etidronate, both irstgeneration bisphosphonates do not have an amino group moiety nitrogencontaining on the r2 long sidechain.
Several recent reports have described osteonecrosis of the jaws onj associated with the use of bisphosphonates. Frontiers doseintensity of bisphosphonates and the risk of. Osteonecrosis of the jaw onj is a wellknown side effect of bisphosphonate bp therapy. The relationship between osteonecrosis of the jaw and bisphosphonate therapy has been described recently. She reported that in may 2009, she underwent an implant rehabilitation with 8 implants and an immediately loaded fixed prosthesis in the maxilla. Antiresorptiverelated osteonecrosis of the jaw aronj is a rare but severe side effect of antiresorptive treatment with bisphosphonates or ranklantibody denosumab in patients with malignant diseases or osteoporosis. Bisphosphonates for osteopenia in postmenopausal women. The earliest report of bisphosphonate associated jaw osteonecrosis occurred after 4 months of treatment. Invasive procedure such as tooth extraction and bone biopsies should be avoided. Further research is needed to increase knowledge about the underlying mechanisms and risk factors for onj, and about. Bisphosphonate and osteonecrosis of the jaw litwiniuk. Effects of bisphosphonates tend to last even after the person stops taking the medicine. Guidelines for bisphosphonateassociated osteonecrosis of the. Bone metastases occur in about 80% of men with advanced prostate cancer, 1 75% of patients with metastatic breast cancer 2 and 30% to 60% of patients with advanced metastatic lung cancer, 3 and are present in 35% of.
The frequency of osteonecrosis of the jaws associated with dental implants is unknown. The following protocols have been developed by the bc cancer agency department of oral oncology. Just as an extraction requires bone turnover to heal, dental implants require bone turnover to maintain osseointegration. Selfhealing lesion of bisphosphonate induced osteonecrosis of. Guidelines for bisphosphonateassociated osteonecrosis of the jaw. Pdf bisphosphonate related osteonecrosis of the jaw. These benefits outweigh the risk of side effects of bisphosphonates, which are minimal. Bisphosphonateassociated adverse events springerlink. Frontiers doseintensity of bisphosphonates and the risk. Risk of jaw osteonecrosis after intravenous bisphosphonates in cancer patients and patients without cancer.
Bisphosphonates are synthetic analogues of pyrophosphate that. Pentoxifylline and tocopherol in the treatment of yearly zoledronic. Oral bisphosphonates spontaneous osteonecrosis of the jaw. Currently their therapeutic use has increased, as also have their adverse effects, one of the most important being the bisphosphonaterelated osteonecrosis of the jaw bronj, a. A current update on osteonecrosis of the jaw and bisphosphonates abstract. Bisphosphonates have been increasingly recommended for use in patients with osteoporosis, pagets disease, hypercalcemia of malignancy, osteolytic bone metastases, and osteolytic lesions of multiple myeloma. It is recommended that you have a good dental exam prior to starting these medications. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. Clinical findings of bisphosphonaterelated osteonecrosis of the jaw bronj bisphosphonaterelated osteonecrosis of the jaw bronj is an area of uncovered bone in the maxillofacial region that did not heal within 8 weeks after identification by health care provider, in a patient who was receiving or had been exposed to bisphosphonate therapy bpt without previous radiation. May 16, 20 oral bisphosphonates are the most commonly prescribed antiresorptive drugs for the treatment of osteoporosis. As a result, they are widely used for the prevention and treatment of osteoporosis. Osteonecrosis of the jaw do bisphosphonates pose a risk.
Bisphosphonates and osteonecrosis of the jaw request pdf. However, there are several adverse effects associated with oral bisphosphonates including the bisphosphonate related osteonecrosis of the jaw bronj. Bisphosphonates are a group of drugs used in the treatment of many common diseases, such osteoporosis, bone metastasis, myeloma. Risk of jaw osteonecrosis after intravenous bisphosphonates. Bisphosphonaterelated osteonecrosis of the jaw in patients with. Incidence in a homogeneous series of patients with newly diagnosed. Severe case of osteonecrosis following implant placement in a. The aim of this study is to describe the radiological features of bisphosphonate osteonecrosis bon in order to aid its prompt recognition. Osteonecrosis of the jaw and the role of bisphosphonates. Osteonecrosis of the jaw is typically associated with trauma to the jaw tooth extraction, history of malignancy andor infections while on bisphosphonate therapy. Medicationrelated osteonecrosis of the jaw mon, mronj is progressive death of the jawbone in a person exposed to a medications known to increase the risk of disease, in the absence of a previous radiation treatment. A 77yearold patient presented in april 20 asking for a consultation. There is little doubt that iv bisphosphonates can cause osteonecrosis of the jaw. Oral bisphosphonates are the most commonly prescribed antiresorptive drugs for the treatment of osteoporosis.
I am simply informing my chiropractic colleagues of one side affect of a very commonly used treatment for osteoporosis. Whilst osteonecrosis of the jaw onj related to the administration of bisphosphonates bps has been investigated for more than 1 decade now, only few data are available on. Risk of osteonecrosis of the jaw in cancer patients taking. Their role is to inhibit osteoclast function, leading to lower bone resorption. Oral use of bisphosphonates for osteonecrosis of the hip has shown some early. Bisphosphonates and osteonecrosis of the jaw annals of. Borromeo department of dentistry, university of melbourne, australia. Understanding bisphosphonates and osteonecrosis of the jaw. Risk factors for bisphosphonate associated jaw osteonecrosis. There is no test to measure onj risk, but some factors are known to raise this risk in very rare. Pathophysiology of bisphosphonatesassociated osteonecrosis of the jaw r21 pa06501. Woo and colleagues 1 highlight the substantial difference in the risk for osteonecrosis of the jaw between patients with cancer who receive high doses of intravenous bisphosphonates and patients with nonmalignant skeletal disorders who receive considerably lower doses, but their recommendations for managing the disorder do not reflect the difference. Onj is specif ically related to the intravenous form of bps and is.
Bisphosphonates and osteonecrosis of the jaws australian. However, the risk of onj for osteoporosis patients taking these types of drugs is very low much lower than the risk of breaking a bone. Bisphosphonates bps have been used for the management of bone metabolic diseases. It may lead to surgical complication in the form of impaired wound healing following oral and maxillofacial surgery, periodontal surgery, or endodontic therapy. To the editor the jama insights article on bisphosphonates for postmenopausal osteoporosis commented that no clinical trials have assessed benefit of treatment with bisphosphonates in women with osteopenia.
Rheumatologists treating bone diseases with bisphosphonate need, therefore, to be aware of this potential risk and plan the prophylaxis, early diagnosis and prevention of potential consequences. Most of the people who have gotten onj while taking bisphosphonates have. This report documents a case of bisphosphonaterelated osteonecrosis of the jaw mronj. Although bisphosphonates have a long list of benefits in the treatment of patients with bone metastases, an increasing number of reports describe the complication of bisphosphonaterelated osteonecrosis of the jaw bronj. However, their paper includes serious misstatements about bisphosphonates and bone. Since 2003 an increasing number of bisphosphonaterelated osteonecrosis of the jaw bronj were reported. Whilst osteonecrosis of the jaw onj related to the administration of bisphosphonates bps has been investigated for more than 1 decade now, only few data are available. Bp induced osteonecrosis of maxilla in a patient who was on a low dose oral bp for osteoporosis and the lesion healed. John bilezikian asks whether there is a relationship between bisphosphonates and osteonecrosis of th. Background the purpose of this study was to describe the clinical characteristics. Their potential to treat other diseases characterized by osteoclastmediated bone resorption has gained attention. Bisphosphonates may take several months to become fully effective. Nih funding opportunities and notices in the nih guide for grants and contracts. Bisphosphonates inhibit bone resorption with relatively few side effects.
Bisphosphonate related osteonecrosis of the jaws bronj in. Keywords bisphosphonates osteonecrosis of the jaws. In osteoporosis and pagets, the most popular firstline bisphosphonate drugs are alendronate and risedronate. Radicalsurgicaltreatmentofbisphosphonaterelatedosteonecrosisofthejaw. Sep 01, 2009 bisphosphonates have been increasingly recommended for use in patients with osteoporosis, pagets disease, hypercalcemia of malignancy, osteolytic bone metastases, and osteolytic lesions of multiple myeloma. Using the populationbased national health insurance claims data of korea from january 1, 2006, through december 3, 2012. Bisphosphonate medications bisphosphonates are a class of medications which include pamidronate aredia. Bisphosphonaterelated osteonecrosis of the jaw in patients with osteoporosis. Bisphosphonates are used to treat osteoporosis, osteitis deformans pagets disease of the bone, bone metastasis with or without hypercalcaemia, multiple myeloma, and other conditions involving fragile, breakable bone. Oral bisphosphonates as a cause of bisphosphonaterelated bisphosphonaterelated osteonecrosis of the jaws bronj in my patient on oral bisphosphonates.
Pdf bisphosphonate associated osteonecrosis of the jaw. Bisphosphonateassociated osteonecrosis of the jaws baonj is a side effect of treatment with bisphosphonate bp. This article is from journal of clinical and experimental dentistry, volume 4. Osteonecrosis of the jaw in patients transitioning from. Bisphosphonates are recommended in the treatment of osteoporosis and some cancers, in which case they prevent the appearance of bone metastasis. Page 1 medicationrelated osteonecrosis of the jaw 2014 update. A medline search 1966january 2007 and a search of international pharmaceutical abstracts 1970january 2007 were. Osteonecrosis of the jaw is a potential complication of nitrogencontaining bisphosphonates. Nov 21, 2006 woo and colleagues 1 highlight the substantial difference in the risk for osteonecrosis of the jaw between patients with cancer who receive high doses of intravenous bisphosphonates and patients with nonmalignant skeletal disorders who receive considerably lower doses, but their recommendations for managing the disorder do not reflect the difference. Severe case of osteonecrosis following implant placement. The patients taking bisphosphonates are at increased risk of developing bisphosphonaterelated osteonecrosis of jaw bronj which is characterised by the presence of an unhealing wound after dental surgery.
Bisphosphonates for osteopenia in postmenopausal women jama. A doubleblind, randomized, placebocontrolled trial of nearly 2000 older women. Medicationrelated osteonecrosis of the jaw wikipedia. The most important factor is the time of exposure to bisphosphonates.
Bisphosphonate drug holidays can be considered for patients who have persisted with bisphosphonate therapy for 3 to 5 years and for those at low risk of fracture. Bisphosphonate complications including osteonecrosis of the. Further research is needed to increase knowledge about the underlying. Bisphosphonateassociated osteonecrosis of the jaw bonj is a rare but painful condition that can affect quality of life. It is recommended that patients should have a dental examination prior to treatment with bisphosphonates. Bisphosphonateinduced osteonecrosis of the jaw request pdf. The condition is called bisphosphonate related osteonecrosis of the jaw bronj 16, which was changed by the.
Read download file report abuse imaging of bisphosphonate related osteonecrosis of the jaw aaoms position paper on bisphosphonaterelated osteonecrosis of the jaw 2009 update approved by the board of trustees january 2009 task force on. Bisphosphonate dental care protocol bisphosphonates and osteonecrosis of the jaw. Bisphosphonate complications including osteonecrosis of. However, bisphosphonates are under scrutiny because of the risk of bisphosphonaterelated osteonecrosis of the jaw.
Guidelines for bisphosphonateassociated osteonecrosis of. Endodontic implications of bisphosphonateassociated osteonecrosis of the jaws aae position statement. This material may not otherwise be downloaded, copied, printed, stored, transmitted. Oral bisphosphonate related osteonecrosis of the jaw. However, several predisposing factors have been identified. To evaluate the level of knowledge of dentists from plovdiv, bulgaria, about possible complications of bisphosphonate therapy of patients in dental practice. Oct 09, 2006 several recent reports have described osteonecrosis of the jaws onj associated with the use of bisphosphonates. Apr 30, 2018 antiresorptiverelated osteonecrosis of the jaw aronj is a rare but severe side effect of antiresorptive treatment with bisphosphonates or ranklantibody denosumab in patients with malignant diseases or osteoporosis. To examine the incidence rates and association between doseintensity, stratified by exposure duration, of bisphosphonates and the risk of osteonecrosis of the jaw among korean osteoporotic patients older than 50 years. It is the r2 sidechain that imparts the potency and method of affect on bone cells. This article aims to provide an overview of bisphosphonates and bronj, to improve the awareness among.
Periodontal disease, dentoalveolar surgery, prior trauma, corticosteroid therapy, immunecompromised state predisposing to increased risk of infection, possible vascular insufficiency and an underlying hypercoagulable state secondary to underlying malignancy. Bisphosphonates for treatment of osteoporosis expected beneits, potential harms, and drug holidays. Osteonecrosis of the jaw in patients treated with bisphosphonates is a relatively rare but well known complication at maxillofacial units around the world. Pamidronate aredia and zoledronate zometa induced avascular necrosis of the jaws. Dec 20, 2012 clinical findings of bisphosphonaterelated osteonecrosis of the jaw bronj bisphosphonaterelated osteonecrosis of the jaw bronj is an area of uncovered bone in the maxillofacial region that did not heal within 8 weeks after identification by health care provider, in a patient who was receiving or had been exposed to bisphosphonate therapy bpt without previous radiation therapy to the. It has been speculated that the medication, especially longterm i. Reports of this complication have increased recently. Bisphosphonate associated osteonecrosis of the jaw. Pdf bisphosphonateinduced osteonecrosis of the jaws. The frequency of osteonecrosis of the jaws associated with dental implants is. Biphosphonatesrelated osteonecrosis of the jaw bialozyk. With a better understanding of this side effect, reported incidences for bronj in oral bisphosphonate users have increased in time. Bisphosphonates can also reduce symptoms that pagets disease can cause, such as bone pain, ringing in the ears, dizziness, and numbness or weakness. Using the populationbased national health insurance claims data of korea from january 1, 2006, through december 3, 2012,730 new.
Bisphosphonateassociated osteonecrosis of the jaws. The american college of prosthodontists agrees with the recommendation for the term, medicationrelated osteonecrosis of the jaw mronj suggested by the american association of maxillofacial surgeons aaoms to replace the previous, morespecific term, bisphosphonate related. Rheumatologists treating bone diseases with bisphosphonate need, therefore, to be aware of this potential risk and plan the prophylaxis, early diagnosis and prevention of. Onj and the medication in question is a family of drugs known as bisphosphonates. Nov 21, 2006 however, their paper includes serious misstatements about bisphosphonates and bone.
However, you should be aware of this rare but potentially. Bisphosphonaterelated osteonecrosis of the jaw a 3years. The incidence of bone metastases is high among patients with advanced cancer. Dental care protocols bisphosphonate medications are linked to a risk of osteonecrosis of the jaw. Mri evaluation of bisphosphonaterelated osteonecrosis of. I am not suggesting patients stop taking bisphosphonates. Osteonecrosis of the jaw associated with bisphosphonates. However, there have been no headtohead dose comparisons of jaw osteonecrosis after iv bisphosphonates for cancer vs noncancer indications. The mechanism of bisphosphonatesinduced osteonecrosis is unclear.
Abstractthe literature describes an increasing presence of bisphosphonateinduced. Bisphosphonates are effective drugs used to treat important medical conditions affecting the skeleton, such as malignancy and osteoporosis. Bisphosphonates and osteonecrosis of the jaw bc cancer. Bisphosphonates are the most clinically important class of antiresorptive agents available. An overview of other treatment options for osteoporosis in women and men is discussed separately. Jun 04, 2006 the risk of jaw osteonecrosis increased with duration of exposure to intravenous bisphosphonate, with the median time of exposure until the development of jaw osteonecrosis of 22 to 39 months. Cumulative incidence of bisphosphonate associated osteonecrosis of the jaw in the oncology patient population. This needs to be considered when developing a dental treatment plan and makes preventive dental care very important.
28 810 1405 132 1413 1219 327 545 252 10 502 1327 1371 86 1407 707 51 1116 17 1240 744 739 733 1236 319 1200 1314 762 670 121 1261 308 485 122 1315 240 1454 1470 854 295 503 410